The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.

The "troubling" trends in the rising costs to US consumers of prescription drugs, including generics, is a big yellow warning sign the biopharmaceutical market is out of balance, largely due to a lack of transparency in how medicines are priced, insisted Dr Stephen Schondelmeyer, a professor of pharmaceutical management and economics and director of the PRIME Institute at the University of Minnesota.